LT3390441T - Žmogaus imunodeficito virusą neutralizuojantys antikūnai - Google Patents
Žmogaus imunodeficito virusą neutralizuojantys antikūnaiInfo
- Publication number
- LT3390441T LT3390441T LTEPPCT/US2016/066658T LT16066658T LT3390441T LT 3390441 T LT3390441 T LT 3390441T LT 16066658 T LT16066658 T LT 16066658T LT 3390441 T LT3390441 T LT 3390441T
- Authority
- LT
- Lithuania
- Prior art keywords
- immunodeficiency virus
- human immunodeficiency
- neutralizing antibodies
- virus neutralizing
- antibodies
- Prior art date
Links
- 241000725303 Human immunodeficiency virus Species 0.000 title 1
- 230000003472 neutralizing effect Effects 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1036—Retroviridae, e.g. leukemia viruses
- C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
- C07K16/1063—Lentiviridae, e.g. HIV, FIV, SIV env, e.g. gp41, gp110/120, gp160, V3, PND, CD4 binding site
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/72—Increased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Biochemistry (AREA)
- AIDS & HIV (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Inorganic Chemistry (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562267652P | 2015-12-15 | 2015-12-15 | |
| PCT/US2016/066658 WO2017106346A2 (en) | 2015-12-15 | 2016-12-14 | Human immunodeficiency virus neutralizing antibodies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| LT3390441T true LT3390441T (lt) | 2021-11-10 |
Family
ID=58737847
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| LTEPPCT/US2016/066658T LT3390441T (lt) | 2015-12-15 | 2016-12-14 | Žmogaus imunodeficito virusą neutralizuojantys antikūnai |
Country Status (37)
| Country | Link |
|---|---|
| US (3) | US10239935B2 (lt) |
| EP (2) | EP3992206A1 (lt) |
| JP (4) | JP6732915B2 (lt) |
| KR (1) | KR102165120B1 (lt) |
| CN (2) | CN114848812A (lt) |
| AR (1) | AR106991A1 (lt) |
| AU (3) | AU2016370591C1 (lt) |
| BR (1) | BR112018012164A2 (lt) |
| CA (1) | CA3008442C (lt) |
| CL (1) | CL2018001587A1 (lt) |
| CO (1) | CO2018006050A2 (lt) |
| CR (1) | CR20180321A (lt) |
| CU (1) | CU20180062A7 (lt) |
| CY (1) | CY1124756T1 (lt) |
| DK (1) | DK3390441T3 (lt) |
| DO (2) | DOP2018000146A (lt) |
| EA (2) | EA201891186A1 (lt) |
| EC (1) | ECSP18045028A (lt) |
| ES (1) | ES2897756T3 (lt) |
| HU (1) | HUE056243T2 (lt) |
| IL (1) | IL259832B (lt) |
| LT (1) | LT3390441T (lt) |
| MA (1) | MA44077A (lt) |
| MX (2) | MX2018007288A (lt) |
| MY (2) | MY196200A (lt) |
| NZ (1) | NZ743713A (lt) |
| PE (1) | PE20181451A1 (lt) |
| PH (1) | PH12018501281A1 (lt) |
| PL (1) | PL3390441T3 (lt) |
| SA (1) | SA518391778B1 (lt) |
| SG (2) | SG10202108793TA (lt) |
| SI (1) | SI3390441T1 (lt) |
| SV (1) | SV2018005710A (lt) |
| TW (2) | TWI735491B (lt) |
| UA (1) | UA125819C2 (lt) |
| WO (1) | WO2017106346A2 (lt) |
| ZA (1) | ZA201803783B (lt) |
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20140294812A1 (en) * | 2013-03-15 | 2014-10-02 | Xencor, Inc. | Fc variants that improve fcrn binding and/or increase antibody half-life |
| WO2015048770A2 (en) | 2013-09-30 | 2015-04-02 | Beth Israel Deaconess Medical Center, Inc. | Antibody therapies for human immunodeficiency virus (hiv) |
| ES2892123T3 (es) | 2014-12-26 | 2022-02-02 | Univ Emory | Derivados antivíricos de N4-hidroxicitidina |
| EP3819310A1 (en) | 2015-10-25 | 2021-05-12 | Sanofi | Trispecific and/or trivalent binding proteins for prevention or treatment of hiv infection |
| NZ743713A (en) | 2015-12-15 | 2020-01-31 | Gilead Sciences Inc | Human immunodeficiency virus neutralizing antibodies |
| MY192090A (en) | 2016-04-13 | 2022-07-26 | Sanofi Sa | Trispecific and/or trivalent binding proteins |
| TWI794171B (zh) | 2016-05-11 | 2023-03-01 | 美商滬亞生物國際有限公司 | Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療 |
| TWI808055B (zh) | 2016-05-11 | 2023-07-11 | 美商滬亞生物國際有限公司 | Hdac 抑制劑與 pd-1 抑制劑之組合治療 |
| EA201892312A1 (ru) | 2017-03-17 | 2019-04-30 | Санофи | Триспецифические и/или тривалентные связывающие белки |
| TWI728250B (zh) | 2017-06-21 | 2021-05-21 | 美商基利科學股份有限公司 | 靶向hiv gp120及cd3之多特異性抗體 |
| GB2581936B (en) | 2017-12-07 | 2021-02-10 | Univ Emory | N4-hydroxycytidine and derivatives and anti-viral uses related thereto |
| SG11202005654QA (en) * | 2017-12-19 | 2020-07-29 | Univ Rockefeller | HUMAN IgG Fc DOMAIN VARIANTS WITH IMPROVED EFFECTOR FUNCTION |
| AU2019226034A1 (en) * | 2018-02-21 | 2020-10-15 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Neutralizing antibodies to HIV-1 Env and their use |
| WO2019226829A1 (en) * | 2018-05-22 | 2019-11-28 | Beth Israel Deaconess Medical Center, Inc. | Antibody therapies for human immunodeficiency virus (hiv) |
| CA3100282A1 (en) * | 2018-06-19 | 2019-12-26 | Nantcell, Inc. | Hiv treatment compositions and methods |
| CR20200653A (es) | 2018-07-03 | 2021-02-11 | Gilead Sciences Inc | Anticuerpos que se dirigen al gp120 de vih y métodos de uso |
| WO2020056383A1 (en) * | 2018-09-13 | 2020-03-19 | Children's National Medical Center | Cells comprising antibodies against human immunodeficiency virus and methods of preparing and using the same |
| WO2020086782A1 (en) * | 2018-10-24 | 2020-04-30 | The Wistar Institute Of Anatomy And Biology | Dna antibody constructs for use against hiv |
| PT3898668T (pt) * | 2018-12-19 | 2023-12-06 | Humabs Biomed Sa | Anticorpos que neutralizam o vírus da hepatite b e suas utilizações |
| BR112021013415A2 (pt) * | 2019-01-07 | 2021-12-28 | Univ Jefferson | Proteínas de fusão multifuncionais e usos das mesmas |
| EP4122537A1 (en) | 2019-03-22 | 2023-01-25 | Gilead Sciences, Inc. | Bridged tricyclic carbamoylpyridone compounds and their pharmaceutical use |
| US11613576B2 (en) | 2019-04-09 | 2023-03-28 | Sanofi | Trispecific binding proteins, methods, and uses thereof |
| TWI762925B (zh) * | 2019-05-21 | 2022-05-01 | 美商基利科學股份有限公司 | 鑑別對使用gp120 v3聚醣導向之抗體的治療敏感之hiv病患的方法 |
| KR20220047977A (ko) * | 2019-07-08 | 2022-04-19 | 캘리포니아 인스티튜트 오브 테크놀로지 | 감소된 다중 반응성을 갖는 항-hiv 백신 항체 |
| EP3999107A1 (en) | 2019-07-16 | 2022-05-25 | Gilead Sciences, Inc. | Hiv vaccines and methods of making and using |
| JP7502861B2 (ja) | 2019-12-27 | 2024-06-19 | 旭化成株式会社 | 標的物質と両親媒性高分子との複合体の形成反応の反応温度の評価方法 |
| AU2021237718B2 (en) | 2020-03-20 | 2023-09-21 | Gilead Sciences, Inc. | Prodrugs of 4'-C-substituted-2-halo-2'-deoxyadenosine nucleosides and methods of making and using the same |
| WO2021207635A1 (en) * | 2020-04-09 | 2021-10-14 | The George Washington University | Prussian blue nanoparticles functionalization with latency reversing agents and broadly neutralizing antibodies, and applications thereof |
| EP4204092A1 (en) | 2020-08-25 | 2023-07-05 | Gilead Sciences, Inc. | Multi-specific antigen binding molecules targeting hiv and methods of use |
| TW202406932A (zh) | 2020-10-22 | 2024-02-16 | 美商基利科學股份有限公司 | 介白素2-Fc融合蛋白及使用方法 |
| AU2021377614A1 (en) | 2020-11-11 | 2023-06-22 | Gilead Sciences, Inc. | METHODS OF IDENTIFYING HIV PATIENTS SENSITIVE TO THERAPY WITH gp120 CD4 BINDING SITE-DIRECTED ANTIBODIES |
| US20230000973A1 (en) * | 2021-06-25 | 2023-01-05 | Janssen Vaccines & Prevention B.V. | Combinations of Vaccines and Neutralizing Antibodies for Treating Human Immunodeficiency Virus Infection in Subjects Undergoing Antiretroviral Treatment |
| US20230203071A1 (en) | 2021-12-03 | 2023-06-29 | Zhimin Du | Therapeutic compounds for hiv virus infection |
| WO2023102523A1 (en) | 2021-12-03 | 2023-06-08 | Gilead Sciences, Inc. | Therapeutic compounds for hiv virus infection |
| WO2023102239A1 (en) | 2021-12-03 | 2023-06-08 | Gilead Sciences, Inc. | Therapeutic compounds for hiv virus infection |
| TW202400172A (zh) | 2022-04-06 | 2024-01-01 | 美商基利科學股份有限公司 | 橋聯三環胺甲醯基吡啶酮化合物及其用途 |
| WO2024006982A1 (en) | 2022-07-01 | 2024-01-04 | Gilead Sciences, Inc. | Therapeutic compounds useful for the prophylactic or therapeutic treatment of an hiv virus infection |
| WO2024015741A1 (en) | 2022-07-12 | 2024-01-18 | Gilead Sciences, Inc. | Hiv immunogenic polypeptides and vaccines and uses thereof |
| US20240083984A1 (en) | 2022-08-26 | 2024-03-14 | Gilead Sciences, Inc. | Dosing and scheduling regimen for broadly neutralizing antibodies |
| WO2024076915A1 (en) | 2022-10-04 | 2024-04-11 | Gilead Sciences, Inc. | 4'-thionucleoside analogues and their pharmaceutical use |
Family Cites Families (85)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5913521B2 (ja) | 1975-06-19 | 1984-03-30 | メイトウサンギヨウ カブシキガイシヤ | 磁性酸化鉄・デキストラン複合体の製造法 |
| US4452773A (en) | 1982-04-05 | 1984-06-05 | Canadian Patents And Development Limited | Magnetic iron-dextran microspheres |
| US4472509A (en) | 1982-06-07 | 1984-09-18 | Gansow Otto A | Metal chelate conjugated monoclonal antibodies |
| US4454106A (en) | 1982-06-07 | 1984-06-12 | Gansow Otto A | Use of metal chelate conjugated monoclonal antibodies |
| PT81498B (pt) | 1984-11-23 | 1987-12-30 | Schering Ag | Processo para a preparacao de composicoes para diagnostico contendo particulas magneticas |
| US4831175A (en) | 1986-09-05 | 1989-05-16 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Backbone polysubstituted chelates for forming a metal chelate-protein conjugate |
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| US7041293B1 (en) | 1990-04-03 | 2006-05-09 | Genentech, Inc. | HIV env antibodies |
| US5571894A (en) | 1991-02-05 | 1996-11-05 | Ciba-Geigy Corporation | Recombinant antibodies specific for a growth factor receptor |
| EP1400536A1 (en) | 1991-06-14 | 2004-03-24 | Genentech Inc. | Method for making humanized antibodies |
| US5587458A (en) | 1991-10-07 | 1996-12-24 | Aronex Pharmaceuticals, Inc. | Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof |
| DK1136556T3 (da) | 1991-11-25 | 2005-10-03 | Enzon Inc | Fremgangsmåde til fremstilling af multivalente antigen-bindende proteiner |
| AU675929B2 (en) | 1992-02-06 | 1997-02-27 | Curis, Inc. | Biosynthetic binding protein for cancer marker |
| US5910486A (en) | 1994-09-06 | 1999-06-08 | Uab Research Foundation | Methods for modulating protein function in cells using, intracellular antibody homologues |
| US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
| US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
| US6815201B2 (en) | 1997-09-08 | 2004-11-09 | The Public Health Research Institute Of The City Of New York, Inc. | HIV-1 gp120 V1/V2 domain epitopes capable of generating neutralizing antibodies |
| US20040132101A1 (en) | 2002-09-27 | 2004-07-08 | Xencor | Optimized Fc variants and methods for their generation |
| US8093357B2 (en) | 2002-03-01 | 2012-01-10 | Xencor, Inc. | Optimized Fc variants and methods for their generation |
| US7317091B2 (en) | 2002-03-01 | 2008-01-08 | Xencor, Inc. | Optimized Fc variants |
| US8388955B2 (en) | 2003-03-03 | 2013-03-05 | Xencor, Inc. | Fc variants |
| US20090010920A1 (en) | 2003-03-03 | 2009-01-08 | Xencor, Inc. | Fc Variants Having Decreased Affinity for FcyRIIb |
| ATE490788T1 (de) | 2003-04-25 | 2010-12-15 | Gilead Sciences Inc | Antivirale phosphonate analoge |
| CA2553946C (en) | 2004-02-06 | 2019-02-26 | University Of Massachusetts | Antibodies against clostridium difficile toxins and uses thereof |
| ES2720618T3 (es) | 2004-07-27 | 2019-07-23 | Gilead Sciences Inc | Análogos de fosfonato de compuestos de inhibidores de VIH |
| WO2006050219A2 (en) | 2004-10-29 | 2006-05-11 | Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Broadly cross-reactive hiv-1 neutralizing human monoclonal antibodies |
| KR101027427B1 (ko) | 2004-11-12 | 2011-04-11 | 젠코어 인코포레이티드 | ＦcRn에 대하여 증가된 결합력을 갖는 Ｆc 변이체 |
| US8367805B2 (en) | 2004-11-12 | 2013-02-05 | Xencor, Inc. | Fc variants with altered binding to FcRn |
| US8546543B2 (en) | 2004-11-12 | 2013-10-01 | Xencor, Inc. | Fc variants that extend antibody half-life |
| US20100056898A1 (en) | 2005-06-13 | 2010-03-04 | Mckenna David R | Objective Methods of Estimating Age of Animals and Carcasses |
| TWI382019B (zh) | 2005-08-19 | 2013-01-11 | Array Biopharma Inc | 作為類鐸受體（ｔｏｌｌ-ｌｉｋｅ ｒｅｃｅｐｔｏｒ）調節劑之胺基二氮雜呯 |
| TW201402124A (zh) | 2005-08-19 | 2014-01-16 | Array Biopharma Inc | 作為類鐸受體（ｔｏｌｌ-ｌｉｋｅ ｒｅｃｅｐｔｏｒ）調節劑之８-經取代苯并氮雜呯 |
| WO2007041635A2 (en) | 2005-10-03 | 2007-04-12 | Xencor, Inc. | Fc variants with optimized fc receptor binding properties |
| EP1803814A1 (en) | 2005-12-27 | 2007-07-04 | SIGMA-TAU Industrie Farmaceutiche Riunite S.p.A. | Method of improving the antibody selection capacity in phage-display library |
| US20080279879A1 (en) | 2006-11-17 | 2008-11-13 | New York University | INDUCTION OF BROADLY REACTIVE NEUTRALIZING ANTIBODIES BY FOCUSING THE IMMUNE RESPONSE ON V3 EPITOPES OF THE HIV-1 gp120 ENVELOPE |
| JP4783325B2 (ja) | 2007-04-09 | 2011-09-28 | 株式会社神戸製鋼所 | 高温排ガスの処理方法 |
| EA024359B1 (ru) | 2007-06-29 | 2016-09-30 | Джилид Сайэнс, Инк. | Пуриновые производные и их применение в качестве модуляторов толл-подобного рецептора 7 |
| EA201200631A1 (ru) | 2007-11-16 | 2012-11-30 | Джилид Сайенсиз, Инк. | Ингибиторы репликации вируса иммунодефицита человека |
| DK2313111T3 (da) | 2008-08-01 | 2013-12-02 | Ventirx Pharmaceuticals Inc | Toll-lignende receptoragonistformuleringer og anvendelse deraf |
| CN102272158B (zh) | 2008-11-12 | 2014-05-07 | 乔治·K·刘易斯 | 源自记忆b细胞的人单克隆抗体的快速表达克隆 |
| AU2009333559B2 (en) | 2008-12-09 | 2015-03-12 | Gilead Sciences, Inc. | Modulators of toll-like receptors |
| EP2398496B1 (en) | 2009-02-20 | 2015-08-05 | International AIDS Vaccine Initiative | Vesicular stomatitis virus vectors encoding hiv env epitopes |
| SI3260136T1 (sl) | 2009-03-17 | 2021-05-31 | Theraclone Sciences, Inc. | Humani imunodeficientni virus (HIV)-nevtralizirajoča protitelesa |
| EP2246364A1 (en) | 2009-04-29 | 2010-11-03 | Pierre Fabre Médicament | Anti CXCR4 antibodies for the treatment of HIV |
| US8338441B2 (en) | 2009-05-15 | 2012-12-25 | Gilead Sciences, Inc. | Inhibitors of human immunodeficiency virus replication |
| RU2580320C2 (ru) | 2009-08-18 | 2016-04-10 | Вентиркс Фармасьютикалз, Инк. | Замещенные бензоазепины в качестве модуляторов toll-подобного рецептора |
| US8691809B2 (en) | 2009-08-18 | 2014-04-08 | Ventirx Pharmaceuticals, Inc. | Substituted benzoazepines as toll-like receptor modulators |
| EP2491035B1 (en) | 2009-10-22 | 2017-08-30 | Gilead Sciences, Inc. | Derivatives of purine or deazapurine useful for the treatment of (inter alia) viral infections |
| US20130165489A1 (en) | 2010-05-03 | 2013-06-27 | The Trustees Of The University Of Pennsylvania | Small Molecule Modulators of HIV-1 Capsid Stability and Methods Thereof |
| US9102614B2 (en) | 2010-07-02 | 2015-08-11 | Gilead Sciences, Inc. | Naphth-2-ylacetic acid derivatives to treat AIDS |
| JP5806735B2 (ja) | 2010-07-02 | 2015-11-10 | ギリアード サイエンシーズ， インコーポレイテッド | Ｈｉｖ抗ウイルス化合物としての２−キノリニル−酢酸誘導体 |
| CN102374226A (zh) | 2010-08-06 | 2012-03-14 | 深圳富泰宏精密工业有限公司 | 套筒、铰链结构及应用该铰链结构的便携式电子装置 |
| EP2611465A4 (en) | 2010-08-31 | 2014-06-04 | Theraclone Sciences Inc | NEUTRALIZING ANTI-VIRUS ANTIBODIES FOR HUMAN IMMUNODEFICIENCY (HIV) |
| RU2551456C2 (ru) | 2010-09-28 | 2015-05-27 | Фудзицу Лимитед | Способ и базовая станция, пользовательское устройство и система для активации режима совместной работы |
| ES2616449T3 (es) | 2010-10-01 | 2017-06-13 | Ventirx Pharmaceuticals, Inc. | Uso terapéutico de un agonista de TLR y terapia de combinación |
| US20120082658A1 (en) | 2010-10-01 | 2012-04-05 | Ventirx Pharmaceuticals, Inc. | Methods for the Treatment of Allergic Diseases |
| KR101416437B1 (ko) | 2010-11-03 | 2014-07-10 | 한국전자통신연구원 | 파장 가변 외부 공진 레이저 발생 장치 |
| WO2012068366A2 (en) | 2010-11-18 | 2012-05-24 | Yale University | Bifunctional molecules with antibody-recruiting and entry inhibitory activity against the human immunodeficiency virus |
| CN106749023A (zh) | 2011-01-12 | 2017-05-31 | 帆德制药股份有限公司 | 作为toll样受体调节剂的取代的苯并氮杂卓 |
| US20140088085A1 (en) | 2011-01-12 | 2014-03-27 | Array Biopharma, Inc | Substituted Benzoazepines As Toll-Like Receptor Modulators |
| WO2012106578A1 (en) * | 2011-02-04 | 2012-08-09 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | HIV NEUTRALIZING ANTIBODIES HAVING MUTATIONS IN CONSTANT DOMAIN (Fc) |
| BR122017025423B1 (pt) | 2011-04-08 | 2021-05-11 | Janssen Sciences Ireland Uc | derivados de pirimidina, seu uso no tratamento de infecções virais e composição farmacêutica que os compreende |
| AP2015008931A0 (en) | 2011-04-21 | 2015-12-31 | Gilead Sciences Inc | Benzothiazole compounds and their pharmaceutical use |
| US8916575B2 (en) | 2011-05-18 | 2014-12-23 | Janssen R&D Ireland | Quinazoline derivatives for the treatment of viral infections and further diseases |
| US9540343B2 (en) | 2011-07-06 | 2017-01-10 | Gilead Sciences, Inc. | Compounds for the treatment of HIV |
| CN102863512B (zh) | 2011-07-07 | 2016-04-20 | 上海泓博智源医药技术有限公司 | 抗病毒化合物 |
| WO2013091096A1 (en) | 2011-12-20 | 2013-06-27 | Boehringer Ingelheim International Gmbh | Condensed triclyclic compounds as inhibitors of hiv replication |
| SG10201608528YA (en) | 2011-12-21 | 2016-12-29 | Novira Therapeutics Inc | Hepatitis b antiviral agents |
| EP2812331B1 (en) | 2012-02-08 | 2019-01-02 | Janssen Sciences Ireland Unlimited Company | Piperidino-pyrimidine derivatives for the treatment of viral infections |
| UY34750A (es) | 2012-04-20 | 2013-11-29 | Gilead Sciences Inc | ?compuestos para el tratamiento del hiv, composiciones,métodos de preparación, intermediarios y métodos terapéuticos?. |
| WO2014022475A2 (en) | 2012-08-03 | 2014-02-06 | Dana-Faber Cancer Institute, Inc. | Compositions and methods for conformationally stabilizing primate immunodeficiency virus envelope glycoprotein trimers |
| EA029266B1 (ru) | 2012-08-10 | 2018-02-28 | Янссен Сайенсиз Айрлэнд Юси | Алкилпиримидиновые производные для лечения вирусных инфекций |
| JP6293765B2 (ja) | 2012-10-10 | 2018-03-14 | ヤンセン・サイエンシズ・アイルランド・ユーシー | ウイルス感染症および他の疾患の処置のためのピロロ［３，２−ｄ］ピリミジン誘導体 |
| BR112015011036B1 (pt) | 2012-11-16 | 2022-02-01 | Janssen Sciences Ireland Uc | Derivados de 2-amino-quinazolina substituídos heterocíclicos, composição farmacêutica |
| KR102527797B1 (ko) | 2012-12-21 | 2023-05-03 | 길리애드 사이언시즈, 인코포레이티드 | 폴리시클릭-카르바모일피리돈 화합물 및 그의 제약 용도 |
| US20140221380A1 (en) | 2012-12-27 | 2014-08-07 | Japan Tobacco Inc. | SUBSTITUTED SPIROPYRIDO[1,2-a]PYRAZINE DERIVATIVE AND PHARMACEUTICAL USE OF SAME AS HIV INTEGRASE INHIBITOR |
| WO2014124457A1 (en) * | 2013-02-11 | 2014-08-14 | University Of Louisville Research Foundation, Inc. | Methods for producing antibodies |
| EA035174B1 (ru) | 2013-02-21 | 2020-05-12 | Янссен Сайенсиз Айрлэнд Юси | Производные 2-аминопиримидина в качестве модуляторов толл-подобных рецепторов tlr7 и/или tlr8 |
| US8993771B2 (en) | 2013-03-12 | 2015-03-31 | Novira Therapeutics, Inc. | Hepatitis B antiviral agents |
| WO2015048770A2 (en) | 2013-09-30 | 2015-04-02 | Beth Israel Deaconess Medical Center, Inc. | Antibody therapies for human immunodeficiency virus (hiv) |
| US9587012B2 (en) | 2013-12-02 | 2017-03-07 | Aaron Diamond Aids Research Center | Bispecific HIV-1 neutralizing antibodies |
| TWI733652B (zh) * | 2014-07-11 | 2021-07-21 | 美商基利科學股份有限公司 | 用於治療ＨＩＶ之ｔｏｌｌ樣受體調節劑 |
| CN107108615B (zh) | 2015-03-04 | 2020-11-20 | 吉利德科学公司 | Toll样受体调节性4,6-二氨基-吡啶并[3,2-D]嘧啶化合物 |
| NZ743713A (en) | 2015-12-15 | 2020-01-31 | Gilead Sciences Inc | Human immunodeficiency virus neutralizing antibodies |
-
2016
- 2016-12-14 NZ NZ743713A patent/NZ743713A/en unknown
- 2016-12-14 MY MYPI2021003644A patent/MY196200A/en unknown
- 2016-12-14 MA MA044077A patent/MA44077A/fr unknown
- 2016-12-14 LT LTEPPCT/US2016/066658T patent/LT3390441T/lt unknown
- 2016-12-14 PL PL16867376T patent/PL3390441T3/pl unknown
- 2016-12-14 PE PE2018001115A patent/PE20181451A1/es unknown
- 2016-12-14 EA EA201891186A patent/EA201891186A1/ru unknown
- 2016-12-14 HU HUE16867376A patent/HUE056243T2/hu unknown
- 2016-12-14 KR KR1020187019806A patent/KR102165120B1/ko active IP Right Grant
- 2016-12-14 TW TW105141486A patent/TWI735491B/zh active
- 2016-12-14 CR CR20180321A patent/CR20180321A/es unknown
- 2016-12-14 ES ES16867376T patent/ES2897756T3/es active Active
- 2016-12-14 DK DK16867376.2T patent/DK3390441T3/da active
- 2016-12-14 TW TW110130315A patent/TWI814056B/zh active
- 2016-12-14 BR BR112018012164A patent/BR112018012164A2/pt active Search and Examination
- 2016-12-14 SG SG10202108793TA patent/SG10202108793TA/en unknown
- 2016-12-14 CN CN202210281565.6A patent/CN114848812A/zh active Pending
- 2016-12-14 AU AU2016370591A patent/AU2016370591C1/en active Active
- 2016-12-14 US US15/379,157 patent/US10239935B2/en active Active
- 2016-12-14 SG SG11201804787UA patent/SG11201804787UA/en unknown
- 2016-12-14 MX MX2018007288A patent/MX2018007288A/es unknown
- 2016-12-14 CU CUP2018000062A patent/CU20180062A7/es unknown
- 2016-12-14 AR ARP160103833A patent/AR106991A1/es unknown
- 2016-12-14 JP JP2018530831A patent/JP6732915B2/ja active Active
- 2016-12-14 CA CA3008442A patent/CA3008442C/en active Active
- 2016-12-14 EA EA202091898A patent/EA202091898A1/ru unknown
- 2016-12-14 CN CN201680079823.5A patent/CN109311967B/zh active Active
- 2016-12-14 SI SI201631372T patent/SI3390441T1/sl unknown
- 2016-12-14 MY MYPI2018702243A patent/MY186414A/en unknown
- 2016-12-14 EP EP21192543.3A patent/EP3992206A1/en active Pending
- 2016-12-14 EP EP16867376.2A patent/EP3390441B1/en active Active
- 2016-12-14 WO PCT/US2016/066658 patent/WO2017106346A2/en active Application Filing
- 2016-12-14 UA UAA201806361A patent/UA125819C2/uk unknown
-
2018
- 2018-06-05 IL IL259832A patent/IL259832B/en unknown
- 2018-06-07 ZA ZA2018/03783A patent/ZA201803783B/en unknown
- 2018-06-11 SA SA518391778A patent/SA518391778B1/ar unknown
- 2018-06-13 CL CL2018001587A patent/CL2018001587A1/es unknown
- 2018-06-13 DO DO2018000146A patent/DOP2018000146A/es unknown
- 2018-06-13 EC ECIEPI201845028A patent/ECSP18045028A/es unknown
- 2018-06-13 SV SV2018005710A patent/SV2018005710A/es unknown
- 2018-06-13 CO CONC2018/0006050A patent/CO2018006050A2/es unknown
- 2018-06-14 PH PH12018501281A patent/PH12018501281A1/en unknown
- 2018-06-14 MX MX2022013524A patent/MX2022013524A/es unknown
-
2019
- 2019-02-12 US US16/273,753 patent/US10882898B2/en active Active
- 2019-12-05 AU AU2019275625A patent/AU2019275625B2/en active Active
-
2020
- 2020-05-14 JP JP2020085079A patent/JP6936361B2/ja active Active
- 2020-12-03 US US17/110,876 patent/US11655285B2/en active Active
-
2021
- 2021-01-29 DO DO2021000022A patent/DOP2021000022A/es unknown
- 2021-08-26 JP JP2021137876A patent/JP7126594B2/ja active Active
- 2021-11-04 AU AU2021261910A patent/AU2021261910B2/en active Active
- 2021-11-10 CY CY20211100980T patent/CY1124756T1/el unknown
-
2022
- 2022-08-16 JP JP2022129584A patent/JP2022163192A/ja not_active Withdrawn
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201803783B (en) | Human immunodeficiency virus neutralizing antibodies | |
| HK1254950A1 (zh) | 中和人體呼吸道合胞體病毒的抗體 | |
| IL253358B (en) | Human antibodies to glycoproteins of Ebola viruses | |
| ZA201706155B (en) | Neutralizing antibodies to gp120 and their use | |
| IL257541A (en) | Neutralizing antibodies to the polyoma virus | |
| HUE060517T2 (hu) | Immunhiányos betegség kezelésére szolgáló eljárások | |
| IL267785A (en) | virus | |
| PT3101132T (pt) | Anticorpo humano anti-transtirretina | |
| EP3218397B8 (en) | Neutralizing antibodies to ebola virus glycoprotein and their use | |
| PL3180356T3 (pl) | Ludzkie przeciwciało anty-fgfr4 | |
| LT3220947T (lt) | Antikūnai, galintys neutralizuoti pasiutligės virusą ir kitus lisavirusus bei jų panaudojimas | |
| PT3390441T (pt) | Anticorpos neutralizantes do vírus da imunodeficiência humana | |
| GB201716047D0 (en) | Virus | |
| EP3271022A4 (en) | Hiv-1 neutralizing antibodies and uses thereof | |
| GB201707093D0 (en) | Viral antigens | |
| GB201700259D0 (en) | Virus | |
| GB201522013D0 (en) | Virus | |
| GB201600380D0 (en) | Modified virus | |
| GB201516936D0 (en) | Virus | |
| GB201403613D0 (en) | Broadly neutralizing monoclonal antibodies against HIV-1 | |
| GB201507419D0 (en) | Virus | |
| GB201507529D0 (en) | Virus preparations | |
| GB201408046D0 (en) | Virus preparations |